Skip to content

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Jun 17, 2026

Data as of Oct 16

▼ SELL$55.4K1,238 shares at $44.75Benjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.
Watch ELVN
Traded
Jun 17, 2026
Disclosed
Jun 22, 2026
Filed
5 days after the trade · late

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Benjamin Hohl, Chief Financial Officer at Enliven Therapeutics, sold ELVN on Jun 17, 2026TRADEDDISCLOSED
ELVNSimilar stocks (XLV — its sector index fund), rebased to ELVN's price on the disclosure day
ELVN since disclosure
−18.8%
after the sale
Similar stocks (XLV) since disclosure
+17.8%
XLV — its sector index fund

Change in closing price from Jun 22, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$59Kdisclosed Jun 22 · filed 5 days after the trade · late
  2. ▼ SELLBenjamin Hohl Chief Financial OfficerELVN Enliven Therapeutics, Inc.$149Kdisclosed Jun 22 · filed 5 days after the trade · late

See every trade on ELVN →